Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)
China · Delayed Price · Currency is CNY 15.39
+0.09 (0.59%)
Jun 1, 2026, 3:04 PM CST
SHE:300497 Revenue
Jiangxi Fushine Pharmaceutical had revenue of 357.76M CNY in the quarter ending March 31, 2026, with 53.09% growth. This brings the company's revenue in the last twelve months to 1.31B, up 22.21% year-over-year. In the year 2025, Jiangxi Fushine Pharmaceutical had annual revenue of 1.18B with 0.61% growth.
Revenue (ttm)
1.31B
Revenue Growth
+22.21%
P/S Ratio
6.33
Revenue / Employee
787.16K
Employees
1,663
Market Cap
8.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18B | 7.14M | 0.61% |
| Dec 31, 2024 | 1.18B | -431.82M | -26.83% |
| Dec 31, 2023 | 1.61B | -37.59M | -2.28% |
| Jan 1, 2023 | 1.65B | 217.72M | 15.23% |
| Jan 1, 2022 | 1.43B | -63.41M | -4.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 15.60B |
| Youcare Pharmaceutical Group | 2.42B |
| China Resources Boya Bio-pharmaceutical Group Co.,Ltd | 1.84B |
| Aurisco Pharmaceutical | 1.68B |
| Liaoning Chengda Biotechnology | 1.31B |
| Shanghai Medicilon | 1.26B |
| Bio-Thera Solutions | 980.25M |
| GemPharmatech | 830.61M |